Why Take Bactrim Without an Infection in Dermatomyositis?
At a Glance
Bactrim is prescribed to dermatomyositis patients as a preventative measure (prophylaxis). Because treatments like high-dose steroids weaken the immune system, Bactrim is necessary to prevent a severe opportunistic fungal lung infection called PJP (Pneumocystis jirovecii pneumonia).
In this answer
5 sections
It is completely understandable to feel confused when your doctor prescribes an antibiotic like Bactrim (trimethoprim-sulfamethoxazole) when you do not currently have an infection. You are being prescribed this medication as prophylaxis—a preventative measure to protect your lungs while your immune system is intentionally suppressed by your dermatomyositis treatments.
The Hidden Risk of “Opportunistic” Infections
To treat dermatomyositis, doctors must use medications that suppress your overactive immune system. This usually involves high-dose corticosteroids (such as taking 20mg or more of prednisone daily) combined with other immunosuppressants [1][2].
While these medications are essential to control your dermatomyositis, they drastically lower your body’s ability to fight off certain germs [1]. One of the most dangerous is a fungus called Pneumocystis jirovecii. In people with healthy immune systems, this fungus is harmless. But when your immune system is suppressed, it can cause a severe lung infection known as PJP (Pneumocystis jirovecii pneumonia) [3][4].
Because PJP takes advantage of a weakened immune system, it is called an opportunistic infection. While the idea of a severe lung infection is scary, taking a preventative medication like Bactrim is highly effective at stopping this fungus before it can ever make you sick [5].
Who is at the Highest Risk?
While anyone on high-dose steroids and immunosuppressants has an elevated risk for PJP, certain factors in dermatomyositis make prevention even more critical:
- High-Dose Steroids: Taking 20mg or more of prednisone daily for an extended period strongly predicts the development of PJP [1][2].
- Low Lymphocyte Counts: Immunosuppressant drugs can lower your lymphocytes (a specific type of white blood cell), which are crucial for fighting off fungal infections like PJP [6][1].
- Specific Dermatomyositis Subtypes: Patients who test positive for the anti-MDA5 antibody or who have interstitial lung disease (ILD) face a much higher risk of both developing PJP and experiencing severe complications from it [3][6][2].
Why Bactrim?
Bactrim (often abbreviated as TMP-SMX) is the first-line, “gold standard” medication used to prevent PJP from ever taking hold [5][7]. It is highly effective at stopping the fungus from reproducing in your lungs [5]. As an added benefit, Bactrim also protects you against other rare opportunistic infections, such as Toxoplasmosis and Nocardia.
To get the protective benefits of Bactrim while minimizing the risk of side effects, doctors often prescribe a low-dose or intermittent regimen [8]. For example, you might only take it three times a week (like on Monday, Wednesday, and Friday) instead of every day [9].
If you are allergic to sulfa drugs or cannot tolerate Bactrim, your doctor has alternative preventative medications they can prescribe, such as dapsone, atovaquone, or pentamidine [10].
Important Safety Considerations
Taking multiple strong medications requires careful coordination. When taking Bactrim, keep the following in mind:
- Drug Interactions: Bactrim can interact with other dermatomyositis treatments. Specifically, taking Bactrim alongside methotrexate can cause a severe, dangerous drop in your blood cell counts. Always ensure your care team (and your pharmacist) has reviewed your complete medication list for interactions.
- Tracking Skin Changes: Bactrim is a “sulfa” drug, which carries a risk of severe allergic skin reactions (such as Stevens-Johnson syndrome) [11]. Because dermatomyositis already causes skin rashes, it can be hard to tell what is a flare and what is an allergy. If you develop a new, worsening, or different type of rash (especially with blisters, peeling, or sores in your mouth) after starting Bactrim, stop the medication and contact your doctor immediately. Do not assume it is just your dermatomyositis flaring up.
What to Watch For
While prophylactic medications are incredibly effective, no prevention strategy is 100% perfect. If you are on high-dose steroids or immunosuppressants, you should contact your doctor if you develop any signs of a lung infection, such as:
- A new, persistent dry cough
- Progressive shortness of breath (especially with activity)
- A fever
Once your dermatomyositis is well-controlled and your steroid dose is lowered (often below 15-20mg of prednisone a day), your doctor will typically stop the preventative antibiotic.
Common questions in this guide
Why do I need to take Bactrim if I don't have an active lung infection?
How long will I need to take preventative antibiotics for dermatomyositis?
Is it safe to take Bactrim if I am also taking methotrexate?
How can I tell an allergic reaction to Bactrim apart from my regular dermatomyositis rash?
What if I am allergic to sulfa drugs and cannot take Bactrim?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How long do you anticipate I will need to stay on Bactrim or another PJP prophylaxis? Does it depend on my prednisone dose dropping below a certain level?
- 2.I am taking several strong immunosuppressants; can we review my entire medication list to ensure Bactrim won't cause dangerous interactions, particularly regarding my white blood cell counts?
- 3.Since my dermatomyositis already gives me a rash, what specific changes to my skin should I look for that might indicate a severe allergic reaction to the Bactrim?
- 4.Taking an intermittent medication (like Mon/Wed/Fri) while managing my daily pills is overwhelming. Do you or the pharmacist have strategies for keeping my schedule organized?
- 5.If I start experiencing stomach upset or a drop in my blood counts from the Bactrim, what is the process for switching to an alternative like dapsone or atovaquone?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.
Ghembaza A, Vautier M, Cacoub P, et al.
Chest 2020; (158(6)):2323-2332 doi:10.1016/j.chest.2020.05.558.
PMID: 32502592 - 2
Characteristics and prognostic analysis of Pneumocystis jirovecii pneumonia in connective tissue diseases patients with interstitial lung disease: a retrospective study.
Shi Y, Chen R, Sun H, et al.
Clinical rheumatology 2025; (44(4)):1653-1663 doi:10.1007/s10067-025-07392-1.
PMID: 40047990 - 3
Pneumocystis jirovecii pneumonia increases the 3-months mortality of anti-MDA5-antibody-positive dermatomyositis patients.
Gao C, Wei G, Zhang C, et al.
Frontiers in immunology 2024; (15()):1504380 doi:10.3389/fimmu.2024.1504380.
PMID: 39669577 - 4
Pneumocystis jirovecii pneumonia in anti-MDA5-positive dermatomyositis: characterisation, risk factors and prognosis.
Yang L, Yang Q, Li J, et al.
Clinical and experimental rheumatology 2026; (44(2)):218-224 doi:10.55563/clinexprheumatol/hpx173.
PMID: 40470551 - 5
Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ, Naylor SM, Roecker AM
The Annals of pharmacotherapy 2016; (50(8)):673-9 doi:10.1177/1060028016650107.
PMID: 27242349 - 6
Analysis of clinical features and risk factors for patients with idiopathic inflammatory myopathy complicated by Pneumocystis jirovecii pneumonia.
Li J, Huang W, Ren F, et al.
Clinical and experimental rheumatology 2026; (44(2)):210-217 doi:10.55563/clinexprheumatol/fpbkc8.
PMID: 40470565 - 7
Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C, Katergi K, Sorin M, et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024; (30(7)):866-876 doi:10.1016/j.cmi.2024.03.037.
PMID: 38583518 - 8
Low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia in HIV-uninfected patients: a systematic review and meta-analysis.
Huang HB, Shi JH, Hu YG, et al.
Frontiers in pharmacology 2025; (16()):1545436 doi:10.3389/fphar.2025.1545436.
PMID: 40735480 - 9
Low-Dose TMP-SMX for Pneumocystis jirovecii Pneumonia Prophylaxis in Pediatric Solid Organ Transplant Recipients.
Chen JK, Guerci J, Corbo H, et al.
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2023; (28(2)):123-128 doi:10.5863/1551-6776-28.2.123.
PMID: 37139252 - 10
Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T, Seo K, Yoshino Y, et al.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2019; (25(5)):351-354 doi:10.1016/j.jiac.2019.01.005.
PMID: 30711257 - 11
Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy.
Climans SA, Grunfeld E, Mason WP, Chan KKW
Neuro-oncology 2022; (24(10)):1738-1748 doi:10.1093/neuonc/noac072.
PMID: 35312784
This page is for informational purposes only and does not replace professional medical advice. Always consult your rheumatologist or healthcare provider before starting or stopping any medications for dermatomyositis.
Get notified when new evidence is published on Dermatomyositis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.